Arcutis Biotherapeutics insider sale and Arista Networks receives $3.6M investment

Arcutis Biotherapeutics reported a strong quarter with $129.86 million in revenue and adjusted earnings of $0.11 per share, beating expectations and raising its 2026 net product sales outlook to $525‑$540 million. Insider Todd Watanabe sold 4,375 shares for $114,275 under a pre‑arranged Rule 10b5‑1 plan, cutting his stake by about 0.61%. Another insider, Patrick Burnett, sold 955 shares for $24,944, a 0.79% reduction.

Arista Networks saw new institutional interest as Mirador Capital Partners LP purchased 21,223 shares valued at roughly $3.6 million. Other investors, including Intrua Financial LLC and NBT Bank, also increased their holdings. In a separate insider transaction, major shareholder Andreas Bechtolsheim sold 260,000 shares for $43.05 million, reducing his ownership by 0.14%.